126 related articles for article (PubMed ID: 17939651)
1. Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502).
Hariprakasha HK; Kosakowska-Cholody T; Meyer C; Cholody WM; Stinson SF; Tarasova NI; Michejda CJ
J Med Chem; 2007 Nov; 50(23):5557-60. PubMed ID: 17939651
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79.
Kosakowska-Cholody T; Cholody WM; Hariprakasha HK; Monks A; Kar S; Wang M; Michejda CJ; Carr BI
Cancer Chemother Pharmacol; 2009 Apr; 63(5):769-78. PubMed ID: 18641988
[TBL] [Abstract][Full Text] [Related]
3. Novel naphthalimide-benzoic acid conjugates as potential apoptosis-inducing agents: design, synthesis, and biological activity.
Wu A; Mei P; Xu Y; Qian X
Chem Biol Drug Des; 2011 Dec; 78(6):941-7. PubMed ID: 21958160
[TBL] [Abstract][Full Text] [Related]
4. HKH40A downregulates GRP78/BiP expression in cancer cells.
Kosakowska-Cholody T; Lin J; Srideshikan SM; Scheffer L; Tarasova NI; Acharya JK
Cell Death Dis; 2014 May; 5(5):e1240. PubMed ID: 24853418
[TBL] [Abstract][Full Text] [Related]
5. 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway.
Xie SQ; Zhang YH; Li Q; Xu FH; Miao JW; Zhao J; Wang CJ
Apoptosis; 2012 Jul; 17(7):725-34. PubMed ID: 22395446
[TBL] [Abstract][Full Text] [Related]
6. Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.
Tan S; Yin H; Chen Z; Qian X; Xu Y
Eur J Med Chem; 2013 Apr; 62():130-8. PubMed ID: 23353750
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA.
Liang GB; Wei JH; Jiang H; Huang RZ; Qin JT; Wang HL; Wang HS; Zhang Y
Eur J Med Chem; 2021 Jan; 210():112951. PubMed ID: 33109400
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma.
Lu YT; Chen TL; Chang KS; Chang CM; Wei TY; Liu JW; Hsiao CA; Shih TL
Bioorg Med Chem; 2017 Jan; 25(2):789-794. PubMed ID: 27939348
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of naphthalimide-polyamine conjugates modified by alkylation as anticancer agents through p53 pathway.
Dai F; He H; Xu X; Chen S; Wang C; Feng C; Tian Z; Dong H; Xie S
Bioorg Chem; 2018 Apr; 77():16-24. PubMed ID: 29316508
[TBL] [Abstract][Full Text] [Related]
10. Development of novel naphthalimide derivatives and their evaluation as potential melanoma therapeutics.
Sk UH; Prakasha Gowda AS; Crampsie MA; Yun JK; Spratt TE; Amin S; Sharma AK
Eur J Med Chem; 2011 Aug; 46(8):3331-8. PubMed ID: 21609852
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.
Christensen MK; Erichsen KD; Trojel-Hansen C; Tjørnelund J; Nielsen SJ; Frydenvang K; Johansen TN; Nielsen B; Sehested M; Jensen PB; Ikaunieks M; Zaichenko A; Loza E; Kalvinsh I; Björkling F
J Med Chem; 2010 Oct; 53(19):7140-5. PubMed ID: 20845961
[TBL] [Abstract][Full Text] [Related]
12. Unprecedented synthesis, in vitro and in vivo anti-cancer evaluation of novel triazolonaphthalimide derivatives.
Li S; Zhong W; Li Z; Meng X
Eur J Med Chem; 2012 Jan; 47(1):546-52. PubMed ID: 22138307
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527
[TBL] [Abstract][Full Text] [Related]
14. DNA binding and anticancer activity of naphthalimides with 4-hydroxyl-alkylamine side chains at different lengths.
Wang K; Wang Y; Yan X; Chen H; Ma G; Zhang P; Li J; Li X; Zhang J
Bioorg Med Chem Lett; 2012 Jan; 22(2):937-41. PubMed ID: 22200595
[TBL] [Abstract][Full Text] [Related]
15. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
Yin H; Xu Y; Qian X; Li Y; Liu J
Bioorg Med Chem Lett; 2007 Apr; 17(8):2166-70. PubMed ID: 17331719
[TBL] [Abstract][Full Text] [Related]
16. A new synthetic agent with potent but selective cytotoxic activity against cancer.
Cholody WM; Kosakowska-Cholody T; Hollingshead MG; Hariprakasha HK; Michejda CJ
J Med Chem; 2005 Jun; 48(13):4474-81. PubMed ID: 15974599
[TBL] [Abstract][Full Text] [Related]
17. Novel naphthalimide derivatives as potential apoptosis-inducing agents: design, synthesis and biological evaluation.
Wu A; Xu Y; Qian X; Wang J; Liu J
Eur J Med Chem; 2009 Nov; 44(11):4674-80. PubMed ID: 19643513
[TBL] [Abstract][Full Text] [Related]
18. Novel naphthalimide-amino acid conjugates with flexible leucine moiety as side chain: design, synthesis and potential antitumor activity.
Wu A; Xu Y; Qian X
Bioorg Med Chem; 2009 Jan; 17(2):592-9. PubMed ID: 19109022
[TBL] [Abstract][Full Text] [Related]
19. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, cytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents.
Tian ZY; Xie SQ; Du YW; Ma YF; Zhao J; Gao WY; Wang CJ
Eur J Med Chem; 2009 Jan; 44(1):393-9. PubMed ID: 18423800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
